Second-line chemotherapy for refractory cancer: Intraperitoneal chemotherapy

✍ Scribed by Maurie Markman

• Book ID: 104594238
• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 568 KB
• Volume: 10
• Category: Article
• ISSN: 8756-0437
• DOI: 10.1002/ssu.2980100411

✦ Synopsis

Over the past decade intraperitoneal therapy in the management of ovarian cancer has evolved from a pharmacokinetic concept into a rationale treatment strategy for a specific subset of patients with this disease. Patients with small-volume residual ovarian cancer (microscopic disease only or macroscopic tumor with largest tumor nodule 50.5 cm in maximum diameter) when treatment is initiated are reasonable candidates to be considered for this therapeutic strategy. At least for salvage platinum-based intraperitoneal therapy, a documented prior response to systemic cisplatin or carboplatin helps to define a patient population who would be anticipated to have the greatest opportunity to respond to a regional treatment approach.